Among them, Lapatinib has been approved for use in patients with advanced or metastatic BC (32, 33); CP724714 (HER2/ErbB2 inhibitor) is also in clinical trials for BC patients (34–36); and the FDA-approved antibacterial drug etanercept (PYR) has shown therapeutic activity in mouse models of BC, with direct tumor suppression and immunostimulatory effects (37). This evidence concerns the gene ERBB2 and neoplasm.